Keros Therapeutics 

Yahoo Finance • last month

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Rise Pre-Bell Friday

Health care stocks were rising pre-bell Friday, with The Health Care Select Sector SPDR Fund (XLV) 0 PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Keros Therapeutics' Duchenne Muscular Dystrophy Treatment Gets FDA's Orphan Drug Designation

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, Wednesday announced that the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dyst... Full story

Yahoo Finance • 2 months ago

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story

Yahoo Finance • 2 months ago

Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright

Investing.com - H.C. Wainwright lowered its price target on Keros Therapeutics (NASDAQ:KROS) to $20.00 from $25.00 on Friday, while maintaining a Buy rating on the stock. According to InvestingPro data, the stock appears undervalued at cur... Full story

Yahoo Finance • 2 months ago

Keros earnings beat by $0.37, revenue topped estimates

Investing.com - Keros (NASDAQ: KROS) reported second quarter EPS of $-0.76, $0.37 better than the analyst estimate of $-1.13. Revenue for the quarter came in at $18.17M versus the consensus estimate of $4.21M. Keros’s stock price closed a... Full story

Yahoo Finance • 2 months ago

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Ker... Full story

Yahoo Finance • 2 months ago

Keros Therapeutics Reports Second Quarter 2025 Financial Results

LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story

Yahoo Finance • 4 months ago

Keros Announces Return of $375 Million in Excess Capital to Stockholders

LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wi... Full story

Yahoo Finance • 4 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story

Yahoo Finance • 4 months ago

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday. In December 2024... Full story

Yahoo Finance • 4 months ago

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company”... Full story

Yahoo Finance • 5 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1’s Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Ur... Full story

Yahoo Finance • 5 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,... Full story

Yahoo Finance • 5 months ago

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wid... Full story

Yahoo Finance • 6 months ago

Keros Therapeutics Announces Review of Strategic Alternatives

Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical... Full story

Yahoo Finance • 6 months ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular... Full story

Yahoo Finance • 9 months ago

KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQ:KROS) on... Full story

Yahoo Finance • 2 years ago

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patie... Full story